Determination of haloperidol in serum by Markit-M Haloperidol and its clinical application

Today, with an increasing medicolegal environment, therapeutic drug monitoring (TDM) has become more essential. The concentration of HPD in the serum is an effective way to safely monitor the clinical use of HPD. Markit-M Haloperidol, an enzyme-immunoassay, was developed as an assay method of HPD in the serum to have a simpler and quicker procedure with a higher sensitivity than the other previous HPD assay, the property of which was studied in the reproducibility test, the recovery test, the dilution test and the specificity test as well as in the correlation to compare with Markit Haloperidol which is the former enzyme immunoassay. Five mg of HPD (i.v.) was injected into schizophrenic patients and followed by a time course of HPD serum concentration; a high correlation (corrective coefficient: r = 0.965) was found bwtween the 2 assays. Other basic examinations showed good results, including high specificity. Its higher sensitivity, speed and simplicity make this new assay advantageous as well as easily applicable and available for HPD drug therapy monitoring.